A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+

Ross Grant¹,²,³ *, Jade Berg¹, Richard Mestayer⁴,⁵, Nady Braidy⁶, James Bennett⁵, Susan Broom⁷ and James Watson⁸

¹Australasian Research Institute, Sydney Adventist Hospital, Wahroonga, NSW, Australia, ²Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, Australia, ³School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia, ⁴NAD+ Research Inc., Springfield, LA, United States, ⁵Springfield Wellness Center, Springfield, LA, United States, ⁶School of Psychiatry, University of New South Wales, NPI, Euroa Centre, Randwick, NSW, Australia, ⁷School of Natural and Behavioural Sciences, William Carey University, Hattiesburg, MS, United States, ⁸Division of Plastic Surgery, Clinical Faculty, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Accumulating evidence suggests that active maintenance of optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer’s disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 µmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 µmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM.

Keywords: NAD+, nicotinamide (NAM), ADP ribose, methyl nicotinamide, nicotinamide mononucleotide

INTRODUCTION

The parent pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is present in all cells of the body and is essential for cell viability and function.

As a cofactor responsible for electron transport into the respiratory chain, NAD+ and its redox couple NADH are central to energy (ATP) production in the mitochondria via oxidative...
and depletion contribute to the neurological dysfunction in this disease. As interventions targeted at restoring NAD+ have been shown in animal models to support healthy aging and improve metabolic function (Yoshino et al., 2011; Mills et al., 2016) and dementia (Long et al., 2015), strategies to raise NAD+ levels in the human are being actively explored.

The most direct method of increasing NAD+ levels is through intravenous (IV) administration. Though data from experimental research is minimal, the significant clinical benefit of IV NAD+ infusion in alcohol withdrawal has been previously reported (O’Holleran, 1961; Mestayer, 2019). Surprisingly, while the oral administration of NAD+ precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) are being enthusiastically investigated for their impact on NAD+ levels (Yoshino et al., 2011, 2018; Mills et al., 2016; Airhart et al., 2017), the metabolic fate and pharmacokinetic properties of IV NAD+ administration are yet to be reported in humans. This study, therefore, presents for the first time the changes in concentrations of NAD+ and its metabolites during an IV infusion of NAD+ in a cohort of healthy male participants.

MATERIALS AND METHODS
Participants
Eleven (Test n = 8, Control n = 3) male participants aged 30–55 years were recruited via advertisements on radio, TV and social media outlets. All participants had a BMI less than 30 kg/m² (Test average BMI = 27.5 ± 2.5 kg/m²; Control average BMI = 24.6 ± 6.5 kg/m²), were not diabetic, smoked less than 1 cigarette and consumed less than 2 standard alcoholic drinks per day. Individuals taking lipid lowering or anti-inflammatory drugs, who had a history of liver or renal failure or recently experienced a microbial infection, trauma or any other significant or untreated medical disorders were excluded from the study. Subjects received monetary compensation for their time and participation, regardless of whether they completed the experiment. Participants were not permitted to use natural health products containing NAD+, NR or Nicotinamide within 14 days prior to and during the course of the study.

Diet Standardization
On the day prior to the NAD+ IV infusion participants consumed an identical niacin-reduced diet and drank only water. No food was consumed on the day of the study until after the final 8 h blood/urine sample had been collected. Participants were encouraged to drink water to remain normally hydrated. No other beverage types were permitted.

To ensure adequate energy intake was maintained for participants during the 6 h infusion the IV solution also contained 0.1% dextrose, providing approximately 2,000 calories over the 6 h infusion period.

Infusion Protocol
Participants were randomized to either the Test (n = 8) or Control (n = 3) group. Participants in the Test group were intravenously administered 750 mg NAD+ in normal saline
(Archway Apothecary, Covington, LA, USA) over a 6 h period (infusion rate \(= \sim 2 \text{ mg/min} \equiv 3 \mu\text{moles/min}\)). This dosage of NAD+ was derived empirically and reflects a common dosing regimen in clinics (e.g., Springfield Wellness Clinic, Springfield, LA, USA) which regularly provide IV NAD+ infusions in clinical practice. Participants in the Control group were intravenously administered normal saline over a 6 h period.

Clinical administration and supervision of the IV infusions and sample collection were carried out at the Springfield Wellness Center, Springfield, LA, USA.

Blood Sample Collection

Baseline (TO) blood samples were collected on all participants after an overnight 12 h fast timed to occur immediately prior to the start of the infusion. Additional samples were then collected at 30, 60, 120 (2 h), 360 (6 h) and 480 (8 h) minutes after the start of the infusion.

Whole blood was collected via standard venepuncture (opposite arm to infusion site) into a 5 mL non-gel heparinized tube. Immediately after the collection, the blood was centrifuged (Archway Apothecary, Covington, LA, USA) over a 6 h period separated and distributed into 5

Table 1

Results were constructed using the peak area ratios (peak area of the metabolite divided by peak area of the selected IS) of each calibrator vs. its concentration.

Internal standards consisted of 2H2NAM (for NAM, methylNAM and ADPR) and \(^{13}\)C\(_2\)-Cyclic AMP (for NMN and NAD+). Note that as isotopic labels are not commercially available for all NAD metabolites, a closely related molecule (structural analog) can also be used (Yamada et al., 2006) provided that it is deemed of similar stability and ionization efficiency during analysis. The internal standards selected in this study have been previously optimized for the related metabolite (Bustamante et al., 2017).

Safety

The safety of IV NAD+ was assessed using liver function tests and clinical observation of any adverse events. Liver function tests consisted of serum, total bilirubin (bili), alkaline phosphatase (ALP), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), lactate dehydrogenase (LD) and aspartate aminotransferase (AST).

Statistical Analysis

Statistical analysis was completed using SPSS version 24 and GraphPad Prism version 8 for windows. An unweighted means, two-way ANOVA with Bonferroni’s multiple comparison post hoc test was used to determine if the mean concentration for analyts tested were different over the 8 h period and between Test and Control groups. The Wilcoxon Signed Ranks test was used to determine if differences in mean liver function test concentrations were significant between baseline and 8 h time points. Differences were considered statistically significant when \(p < 0.05\).

Ethics

This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. Ethical approval was obtained from the William Carey University Institutional Review Board, Hattiesburg, MS (Protocol #2017-12). Informed consent was obtained from all participants.

RESULTS

Safety

No adverse events were observed during the 6 h infusion with either placebo (saline) or test (NAD+) cohorts. A significant decrease in activity (1.3, 57, 3.6 units/L) for the liver function enzymes GGT, LD and AST, respectively was observed at 8 h after initiation of the NAD+ infusion (Table 1). No significant change in activity for any liver function marker was apparent at 8 h in the placebo (saline) treated samples, however low sample number may reduce discrimination sensitivity. A significant increase of 2.75 \(\mu\text{moles/L}\) in plasma bilirubin was also observed. However, none of the changes were considered clinically significant.
TABLE 1 | The Wilcoxon Signed Ranks test was used to determine if differences in mean liver function test concentrations were significant between baseline and 8 h time points.

| Reference range | Group | Time 0 h Mean (SD) | Time 8 h Mean (SD) | p (T0 vs. T8) |
|-----------------|-------|-------------------|-------------------|--------------|
| Albumin (g/L)   | Test  | 46.0 (2.5)        | 45.5 (2.9)        | ns           |
|                 | Control| 42.0 (5.7)        | 42.9 (4.5)        | ns           |
| Total protein (g/L) | Test | 64.1 (5.5)       | 63.7 (6.5)        | ns           |
|                 | Control| 62.7 (4.9)       | 62.1 (6.2)        | ns           |
| Total bilirubin (µmol/L) | Test | 7.5 (0.3)         | 7.5 (0.3)         | ns           |
|                 | Control| 7.3 (0.5)         | 7.2 (0.6)         | ns           |
| ALP (units/L)   | Test  | 25.5 (17.4)       | 25.5 (17.4)       | <0.05        |
|                 | Control| 26.5 (10.3)       | 26.5 (10.3)       | ns           |
| ALT (units/L)   | Test  | 18.7 (4.9)        | 18.7 (4.9)        | ns           |
|                 | Control| 17.7 (4.9)        | 17.7 (4.9)        | ns           |
| GGT (units/L)   | Test  | 2.3 (0.7)         | 2.3 (0.7)         | <0.05        |
|                 | Control| 2.4 (1.2)         | 2.4 (1.2)         | ns           |
| LD (units/L)    | Test  | 25.6 (6.3)        | 25.6 (6.3)        | <0.05        |
|                 | Control| 25.5 (6.6)        | 25.5 (6.6)        | ns           |
| AST (units/L)   | Test  | 15.6 (1.7)        | 15.6 (1.7)        | <0.05        |
|                 | Control| 15.7 (1.9)        | 15.7 (1.9)        | ns           |

Differences were considered statistically significant when p < 0.05.

Plasma
A continuous infusion of NAD+ at a rate of 3 µmoles/min resulted in a significant (398%) increase in plasma NAD+ levels only at the 6 h time point (i.e., end of infusion) relative to baseline (p < 0.0001). This was significantly different from the 6 h saline-treated control (p < 0.001).

NAD+ levels remained elevated at 8 h (i.e., 2 h post-infusion) relative to baseline and saline treated control samples.

Plasma NAD+ levels did not change significantly from baseline across the 8 h assessment period in saline treated control samples (Figure 1A).

Similar to the changes observed for NAD+, plasma levels of the NAD+ metabolite nicotinamide (NAM) increased significantly by 499% at the end of the NAD+ infusion (i.e., 6 h) relative to baseline (p < 0.0001). This was likewise significantly different to the 6 h saline treated control (p < 0.001).

At the 8 h time point (i.e., 2 h after end of infusion), NAM levels between the control and treated groups were no longer significantly different (p > 0.05).

NAM levels for saline treated control samples did not change significantly across the 8 h time period (p > 0.05, Figure 1B).

Consistent with the changes observed for NAM, plasma levels of the NAD+ metabolite ADPR increased significantly by 393% at the end of the NAD+ infusion (i.e., 6 h) relative to baseline (p < 0.0001). This was significantly different to the 6 h saline treated control (p < 0.0001).

At the 8 h time point (i.e., 2 h after the end of infusion), ADPR levels remained 305% above baseline (p < 0.0001). However, this was not significantly greater than ADPR levels in the saline treated control samples at the same time point (p > 0.05).

ADPR levels for saline treated control samples did not change significantly across the 8 h time period (p > 0.05, Figure 1C).

A Spearman’s correlation analysis between group averages across the 8 h time points for the two NAD+ catabolic metabolites, NAM and ADPR, produced a correlation coefficient of 1.00 (p < 0.001).

Again, consistent with the changes observed for NAM, plasma levels of the NAM metabolite, methyl-nicotinamide (meNAM) increased significantly to 350% at the end of the NAD+ infusion (i.e., 6 h) relative to both baseline (p < 0.0001) and the 6 h saline treated control (p < 0.01).

At the 8 h time point (i.e., 2 h after end of infusion) meNAM levels remained 393% above baseline (p < 0.0001) and significantly greater than the saline treated control samples at the same time point (p < 0.05).

meNAM levels for saline treated control samples did not change significantly across the 8 h time period (p > 0.05, Figure 1D).

Plasma levels of NMN, a metabolite of NAM via the anabolic salvage pathway, was significantly elevated (472%) only at the 8 h time point (i.e., 2 h after end of infusion, p < 0.05).

NMN levels for saline treated control samples did not change significantly across the 8 h time period (p > 0.05, Figure 1E).

Urine
The continuous IV infusion of NAD+ at a rate of 3 µmoles/min resulted in a significant (538%) increase in the urine NAD+ excretion rate at the 6 h time point (i.e., end of infusion) relative to that excreted at 30 min (p < 0.0001). This was also significantly different to the amount of urine NAD+ excreted at 6 h by the saline treated controls (p < 0.05).

The amount of NAD+ excreted in urine decreased by 43% (p < 0.05) at 8 h (i.e., 2 h post-infusion) relative to the peak excretion at the 6 h time point.

The urine excretion rate for NAD+ did not change significantly across the 8 h assessment period in saline treated control samples (Figure 2A).

The excretion rate of the NAD+ metabolite NAM did not change significantly across the 8 h test period and was not different to the observed NAM excretion rate for the saline treated controls (Figure 2B).

The urine excretion rate of the NAM metabolite meNAM was significantly increased (403%) at the 6 h time point (i.e., end
FIGURE 1 | Changes in plasma nicotinamide adenine dinucleotide (NAD+) and metabolites over 8 h [1st 6 h consisting of a continuous (3 \(\mu\) moles/min) NAD+ IV infusion]. (A) NAD+, (B) Nicotinamide (NAM), (C) adenosine phosphoribose (ADPR), (D) methyl nicotinamide (MeNAM), (E) nicotinamide mononucleotide (NMN).

\(^*\)p < 0.05, \(^{**}\)p < 0.01, \(^{***}\)p < 0.001, \(^{****}\)p < 0.0001, as indicated. Two-way ANOVA with Bonferroni’s multiple comparison post hoc test was used to determine if the mean concentration for analysts tested were different over the 8 h period and between Test (n = 8) and Control (n = 3) groups.
FIGURE 2 | Changes in urine NAD+ and metabolites over 8 h (1st 6 h consisting of a continuous, 3 µmoles/min, NAD+ IV infusion). (A) NAD+, (B) NAM, (C) meNAM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as indicated. Two-way ANOVA with Bonferroni’s multiple comparison post hoc test was used to determine if the mean concentration for analysts tested were different over the 8 h period and between Test (n = 8) and Control (n = 3) groups.

DISCUSSION

A growing interest in NAD+ based therapies including NAD+ infusions has highlighted the need for a clearer understanding of the fate of NAD+ and its metabolites following IV administration. The current study documents changes in levels of NAD+ and key metabolites in both plasma and urine over 8 h using a typical clinical dosing regimen of 750 mg NAD+ administered IV over a 6 h period.

Importantly infusion of NAD+ did not produce any observable adverse events in the test cohort but rather reduced plasma activities of enzymes indicative of hepatic stress such as the intrahepatic LD and AST and the post-hepatic (bile duct) enzyme GGT suggesting that the integrity of both intra hepatic and post-hepatic tissue was enhanced even within the relatively short 8 h time frame. The rise in bilirubin, a red cell degradation product, at 8 h may reflect either a very small increase in red cell turnover, as can occur due to infusion induced hemeolysis, or reduced heme metabolism (Table 1). However, given the very low magnitude of this change, this was not considered clinically relevant.

As expected, in saline-treated (i.e., control) participants, plasma levels of NAD+ and metabolites NAM and ADPR and the NAM metabolites, NMN and meNAM remained essentially unchanged across the 8 h period. However, an apparent decrease in NAM, meNAM and ADPR were observed between 30 min and 6 h, most likely due to a saline dilution effect. Consistent with this notion, values for these analytes were seen to return to baseline levels at 8 h (i.e., 2 h after the end of the saline infusion).

Unexpectedly however in NAD+ infused participants, plasma NAD+ levels failed to rise until after the 2 h time point reaching a maximum of ~400% above baseline for NAD+ and metabolites NAM, meNAM and ADPR (398%, 409%, 393%, respectively) only at the 6 h time point (Figures 1A–E). This was internally consistent with the peak of urinary excretion for both NAD+ and meNAM also occurring at 6 h before rapidly decreasing after the end of the infusion (Figures 2A–C).

NAD+ was infused at a constant rate of 3 µmoles/min. Therefore 90 µmoles of NAD+ was being infused directly into the vascular compartment every 30 min delivering a total of 1,080 µmoles by the end of the infusion at 6 h. Intravascular mixing from any point of infusion occurs within ~2 min; assuming an average blood volume of 5, the added NAD+, in the absence of significant metabolism or absorption, would correspond to an additional rise in (NAD+) of at least 18 µM, every 30 min across the 6 h of infusion. While an increase of this magnitude is well within this study’s analytical detection limits no increase in either NAD+ or its metabolites, were observed until after 2 h (i.e., at the 6 h time point) in either plasma or urine. This unexpected observation indicates a rapid, and for at least the first 2 h, complete tissue uptake and/or metabolism of NAD+ and/or its metabolites.

A number of enzymes can achieve effective NAD+ catabolism including the sirtuins (SIRTs 1–7) the adenosine diphosphate (ADP)–ribose transferases (ARTs) and poly(ADP-ribose) polymerases (PARPs 1–17) and the cyclic ADP-ribose (cADPR) synthases (CD38, CD157). Extracellular NAD+
pyrophosphatases present in human serum can also degrade NAD+ to AMP and NMN (Schmidt-Brauns et al., 2001). The cell-surface protein CD73 also converts NMN into NR, which easily crosses cell membranes for potential resynthesis to NAD+. Importantly the NAD+ catabolizing glycohydrolases, CD38 and CD157, ecto-nucleotide pyrophosphatase (CD203a) and the NMN catabolizer CD73 are ectoenzymes found on a wide variety of cells including lymphoid, granulocytic, neuronal and endothelial cells (Wei et al., 2014) and plasma soluble NAD glycohydrolases may also be present (Figure 3; Funaro et al., 2009). The parallel rise of plasma NAM and ADPR (correlation coefficient of 1.000, \( p < 0.001 \), data not shown) strongly suggests that at least by 6 h a major fate of NAD+ is metabolism through cleavage of the glycosidic ADPribose–nicotinamide linkage to NAM and ADPR, by-products symptomatic of NAD glycohydrolase (e.g., CD38) activity. This is consistent with evidence by others where CD38, in particular, has been shown to have a primary role in controlling extracellular NAD+ levels (Wei et al., 2014). Adult human erythrocytes are CD38 positive and express high levels of NAD+ glycohydrolase activity, cleaving exogenous NAD+ to supply erythrocytes with ADP ribose that can be efficiently taken up into the cell (Kim et al., 1993; Albeniz et al., 2004). The absence of any rise in either NAD+ or metabolites, in plasma or urine, until after the first 2 h of the infusion indicates that NAD+ and/or its metabolites are trafficked out of the extracellular vascular space and efficiently sequestered into tissue or extravascular compartments as NAD+ and/or its metabolites during this time period.

Though PARP and sirtuins are involved in NAD+ catabolism, as intracellular enzymes with representatives in cytoplasm, nucleus and mitochondria they are unlikely to directly impact extracellular NAD+ levels. However, these enzymes may be expected to respond to changes in intracellular concentrations of NAD+, NAM and NR that may arise from exogenously supplied NAD+. Figure 4 summarizes schematically the possible fates of exogenous NAD+.

While significant capacity exists for the rapid degradation of the exogenously supplied IV NAD+ into constituent metabolites, it is also worth noting that uptake of extracellular NAD+ may also be occurring. As NAD+, has an overall negative charge it is unable to cross cellular membranes passively and therefore must be actively transported across the membrane. That this occurs has been shown by a number of researchers who have reported that exogenous NAD+ applied to a variety of human cell types does indeed result in a significant elevation of intracellular NAD+ (Ying et al., 2003; Zhu et al., 2005; Billington et al., 2008; Pittelli et al., 2011; Felici et al., 2013). While the mechanism(s) involved are not yet fully characterized, Alano et al. (2010) reported that exogenous NAD+ could enter neurons through P2X7 gated channels and others have consistently observed the transport of NAD+ across membranes by connexin 43 (CX43) hemichannels, even at concentrations as low as 250 pM (Billington et al., 2008). As connexins have a wide distribution in human tissue and CX43 appears to be the most ubiquitous connexin in many cell types the potential for rapid uptake of NAD+ cannot be discounted.

Thus cellular uptake and/or metabolism of NAD+ and metabolites NAM and ADPR and secondary metabolites meNAM and NMN appeared to proceed at pace with the 3 \( \mu \)moles/min NAD+ infusion for at least the first 2 h.
Either NAD+ and/or the primary metabolites tested are being efficiently sequestered during this first 2–6 h period or secondary metabolites are also being formed. ADPR can be recycled to produce NAD+ from NAM (Figure 4) or further metabolized via ectoenzymes such as CD203a (NAD+ pyrophosphatase) to produce AMP which can be further rapidly metabolized to adenosine by CD73 a 5′-nucleotidase (Bogan and Brenner, 2010; Horenstein et al., 2016; Morandi et al., 2018). In support of this hypothesis, an increase in blood adenosine levels has been recognized by others as a consequence of extracellular NAD+ infusion (Szczepañska-Konkel et al., 2003). NAM can also be metabolized to NMN via the salvage pathway before resynthesis to NAD+ (Figures 3, 4) or acted on by hepatic methyltransferases to produce N1-methylnicotinamide which may either be excreted directly or further converted to N-methyl-2-pyridone-5-carboxamide (2PY, +99% of meNAM) and N-methyl-4-pyridone-3-carboxamide (4PY, ~0.25% of meNAM) before excretion (Shibata and Matsuo, 1989; Okamoto et al., 2003).

It is evident that at the dosing regimen used the mechanisms involved in the metabolism and sequestering of NAD+ and metabolites have reached saturation sometime after 2 h resulting in a significant elevation of plasma NAD+ and accumulation of all metabolites tested (NMA, ADPR, meNAM and NMN) at 6 h. As mentioned previously these data support the view that one major pathway for NAD+ metabolism under these conditions is the cleavage of the glycosidic bond, by ectoenzymes such as CD38 to produce NAM and ADPR. However, the rise in plasma...
NMN after 2 h also suggests that exogenous NAD+ is likely acted on by extracellular NAD+ pyrophosphatases, elevating plasma NMN and releasing AMP as an additional metabolite.

In summary, this study revealed for the first time that: (a) at a flow rate of 3 μmol/min all exogenously infused NAD+ was rapidly and completely removed from the plasma for at least the first 2 h; (b) the increase in metabolic bi-products analyzed is consistent with NAD+ glycohydrolases and NAD+ pyrophosphatase activity; and (c) the urinary excretion products arising from NAD+ infusion include native NAD+ and meNAM but not NAM.

While the findings of this investigation are novel and go some way to advancing our understanding of the timed fate of exogenous NAD+ in humans, limitations were identified. To improve overall metabolic reckoning future studies should investigate changes in red cell NAD+ and metabolites and urinary excretion of the secondary meNAM metabolites, 2PY and 4PY. In addition, it will likely be useful to assess the impact of exogenous NAD+ on changes in purine metabolism which should include at least assessment of plasma and red cell AMP and adenosine. The use of animal models may also help to clarify the relative involvement of the various metabolic pathways through the use of suitable pharmacological inhibitors and tissue sampling.

In conclusion, this study was able to reveal for the first time some very useful, previously unknown, information about the fate of exogenous IV NAD+ in humans including, the overall safety and tolerability of an IV NAD+ infusion at a rate of 3 μmol/min, the rapid sequestering of NAD+ from the plasma, the likely contribution of both NAD+ glycohydrolase and NAD+ pyrophosphate activity in the metabolism of NAD+ and the apparent efficient renal tubular reabsorption of NAM. However additional research is required to fully reveal the complex metabolic fate of this important molecule. Further, characterization of these changes will help progress the development and improvement of NAD+ based treatment regimens for disorders which are likely to benefit from increased NAD+ availability including conditions requiring increased cellular regeneration and repair such as Alzheimer’s and other neurodegenerative dementias.

DATA AVAILABILITY

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by William Carey University Institutional Review Board, Hattiesburg, MS (Protocol #2017-12). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RG participated in study design and oversight, critical discussion and manuscript authorship. JBer participated in study design, critical discussion, data collection, statistical analysis, manuscript drafting and manuscript review. RM participated in study design, critical discussion, clinical supervision and manuscript review. NB participated in biochemical analysis and manuscript review. JW participated in study design, critical discussion and manuscript review. JBen participated in data collection, and manuscript review. SB participated in study design and manuscript review. All authors have reviewed, read and approved the final version of the manuscript, and agree with the order of presentation of the authors.

FUNDING

This study was funded jointly by the NAD+ Research Inc., (LA, USA) and the Australasian Research Institute Incorporation (Sydney, Australia) and was conducted at Springfield Wellness Center, Springfield, LA, USA.

ACKNOWLEDGMENTS

We wish to thank Archway Apothecary Pty Limited, LA, USA for their gratis supply of IV NAD+ for this project.

REFERENCES

Abeti, R., and Duchen, M. R. (2012). Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer’s disease. Neurochem. Res. 37, 2589–2596. doi: 10.1007/s11064-012-0895-x

Aihart, S. E., Shireman, L. M., Risler, L. J., Anderson, G. D., Nagana Gowda, G. A., Rafferty, D., et al. (2017). An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One 12:e0186459. doi: 10.1371/journal.pone.0186459

Alano, C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T. M., and Swanson, R. A. (2010). NAD+ depletion is necessary and sufficient for PARP-1 mediated neuronal death. J. Neurosci. 30, 2967–2978. doi: 10.1523/JNEUROSCI.5552-09.2010

Albeniz, I., Demir, O., Nurten, R., and Bermek, E. (2004). NAD glycohydrolase activities and adp-ribose uptake in erythrocytes from normal subjects and cancer patients. Biosci. Rep. 24, 41–53. doi: 10.1023/b:bire.0000037755.42767.a4

Billington, R. A., Travelli, C., Ercolano, E., Galli, U., Roman, C. B., Grolla, A. A., et al. (2008). Characterisation of NAD+ uptake in mammalian cells. J. Biol. Chem. 283, 6367–6374. doi: 10.1074/jbc.M706204200

Bogan, K., and Brenner, C. (2010). S'-nucleotidases and their new roles in NAD+ and phosphate metabolism. New J. Chem. 34, 845–853. doi: 10.1039/b9nr00758h

Braidy, N., Guillemain, G. J., Mansour, H., Chan-Ling, T., Poljak, A., and Grant, R. (2011). Age related changes in NAD+ metabolism oxidative stress and sirt1 activity in wistar rats. PLoS One 6:e19194. doi: 10.1371/journal.pone.0019194

Braidy, N., Poljak, A., Grant, R., Jayasena, T., Mansour, H., Chan-Ling, T., et al. (2014). Mapping NAD+ metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence. Biogerontology 15, 177–198. doi: 10.1007/s10522-013-9489-5

Bustamante, S., Jayasena, T., Richani, D., Gilchrist, R., Wu, L., Sinclair, D., et al. (2017). Quantifying the cellular NAD+ metabolome using a tandem
liquid chromatography mass spectrometry approach. Metabolomics 14:15. doi: 10.1007/s11306-017-1310-z
Clement, J., Wong, M., Poljak, A., Sachdev, P., and Braidy, N. (2018). The plasma NAD+ metabolome is dysregulated in “normal” aging. Rejuvenation Res. 22, 121–130. doi: 10.1089/rej.2018.2077
Ciazzo, A., Tarantini, S., Yabluchanskii, A., Balasubramanian, P., Kiss, T., Farkas, E., et al. (2019). Role of endothelial NAD+ deficiency in age-related vascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 316, H1253–H1266. doi: 10.1152/heartphys.00391.2019
Essuman, K., Summers, D. W., Sasaki, Y., Mao, X., DiAntonio, A., and Milbrandt, J. (2017). The SARM1 toll-interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron 93, 1334.e5–1343.e5. doi: 10.1016/j.neuron.2017.02.022
Felici, R., Lapucci, A., Ramazzotti, M., and Chiarrugi, A. (2013). Insight into molecular and functional properties of NMNAT3 reveals new hints of NAD homeostasis within human mitochondria. PLoS One 8:e76938. doi: 10.1371/journal.pone.0076938
Funaro, A., Ortolan, E., Bovino, P., Lo Buono, N., Nacci, G., Parrotta, R., et al. (2009). Ectoenzymes and innate immunity: the role of human CD157 in leukocyte trafficking. Front. Biosci. 14, 929–943. doi: 10.2741/3287
Goldberger, J. (1914). The etiology of Pellagra: the significance of certain epidemiological observations with respect thereto. Public Health Rep. 29, 1683–1686. doi: 10.2307/4570920
Guest, J., Grant, R., Mori, T. A., and Croft, K. D. (2014). Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. Public Health Rep. 129, 1683–1686. doi: 10.2307/4570920
Guest, J., Grant, R., Mori, T. A., and Croft, K. D. (2014). Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. Public Health Rep. 129, 1683–1686. doi: 10.2307/4570920
Horenstein, A., Quarona, V., Toscani, D., Costa, F., Chillemi, A., Pistoia, V., et al. (2016). Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Mol. Med. 22, 694–704. doi: 10.2119/molmed.2016.00198
Kim, U., Han, M. K., Park, B. H., Kim, H. R., and An, N. H. (1993). Function of NAD glycohydrolase in ADP-ribos uptake from human erythrocytes. Biochim. Biophys. Acta 1178, 121–126. doi: 10.1016/0167-4889(93)90001-6
Long, A. N., Owens, K., Schlapall, A. E., Kristian, T., Fishman, P. S., and Schuh, R. A. (2015). Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol. 15:19. doi: 10.1186/s12883-015-0272-1
Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., Guillemin, G. J., et al. (2018). The role of mitochondrial respiratory deficits in an Alzheimer disease-relevant murine model. J. Physiol. Pharmacol. 54, 163–173.
Wu, J., Jin, Z., Zheng, H., and Yan, L. J. (2016). Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications. Diabetes Metab. Syndr. Obes. 9, 145–153. doi: 10.2147/dmsso.s106807
Yamada, K., Hara, N., Shibata, T., Osago, H., and Tsuchiya, M. (2006). The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Biochem. 352, 282–285. doi: 10.1016/j.ab.2006.02.017
Ying, W. (2015). Roles of NAD+, PARP-1, and sirtuins in cell death, ischemic brain injury, and synchrotron radiation X-ray-induced tissue injury. Front. Neurosci. 9:e42357. doi: 10.3389/fnins.2015.0042357
Ying, W. (2013). The SARM1 toll/interleukin-1 receptor domain mediates by NAD+ depletion and can be relieved by NAD+ intermediates: the biology and therapeutic potential of NNMN and NR. Cell. Metab. 27, 513–528. doi: 10.1016/j.cmet.2017.11.002
Yoshino, J., Mills, K. F., Yoon, M. J., and Imai, S. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536. doi: 10.1016/j.cmet.2011.08.014
Zhao, M., Ottenberg, G., Stoffers, J. T., Winter, L., Pumphrey, G., et al. (2015). Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. Brain 138, 992–1008. doi: 10.1093/brain/awv002
Zhu, K., Swanson, R. A., and Ying, W. (2005). NADH can enter into astrocytes to block PARP-1-mediated astrocyte death. Neuroreport 16, 1209–1212. doi: 10.1097/01.wnr.00001756-200508010-00015
Zhu, X., Sua, B., Wang, X., Smitha, M. A., and Perry, G. (2007). Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64, 2202–2210. doi: 10.1007/s00018-007-7218-4

Conflict of Interest Statement: RM is a director of NAD+ Research Inc., and medical director of the Springfield Wellness Center which uses IV NAD as a clinical therapy. SB received consulting fees from NAD+ Research Inc. Any remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Grant, Berg, Mestayer, Braidy, Bennett, Broom and Watson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.